01. Doctor Overview
Dr. Jula Veerapong is a board-certified surgical oncologist at Moores Cancer Center. The center is part of the University of California San Diego, where Dr. Veerapong is also an assistant professor. He specializes in gastrointestinal cancers, with a focus on treating cancers of the peritoneal lining, like peritoneal mesothelioma. He has experience with several common mesothelioma treatments, including:
Dr. Veerapong also researches treatments for gastrointestinal malignancies. He was the principal investigator on a study of CRS/HIPEC patient outcomes. He also developed a HIPEC program at the Saint Louis University School of Medicine. This unique program brought in 100 patients from all across the United States.
Dr. Veerapong is sought out as a national and international expert in his field. His scholarly work has appeared in journals like Cancer Research, Journal of Gastrointestinal Surgery and Clinical Cancer Research.
Dr. Veerapong developed his skills at a number of prestigious cancer centers. He completed a surgical oncology fellowship at the University of Texas MD Anderson Cancer Center, followed by a residency in general surgery at the University of Chicago Medical Center. Before assuming his current associate professor role, Dr. Veerapong was an assistant professor at the Saint Louis University School of Medicine.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Gastrointestinal Surgery
Other Interests & Specialties: Peritoneal mesothelioma, colorectal cancer, soft tissue sarcoma and peritoneal surface malignancies.
Certifications, Awards & Accolades: American Board of Surgery Certification in General Surgery, Society of Surgical Oncology member, Society for Surgery of the Alimentary Tract member, Alpha Omega Alpha Honor Medical Society member, 2015 Vallee L. Willman Award for Excellence in Surgical Education
Education & Experience:
- Medical Degree from University of Illinois College of Medicine
- Fellowship at University of Texas MD Anderson Cancer Center
- Residency at University of Chicago, Pritzker School of Medicine
Aso visual abstract: neighborhood level socioeconomic disadvantage predicts outcomes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy. Ann Surg Oncol. 2023 Dec;30(13):8178–9.
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis. Surg Endosc. 2023 Jul;37(7):5644–51.
Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the us hipec collaborative. Ann Surg Oncol. 2023 Mar;30(3):1840–9.
Crs/hipec with major organ resection in peritoneal mesothelioma does not impact major complications or overall survival: a retrospective cohort study of the us hipec collaborative. Ann Surg Oncol. 2020 Dec;27(13):4996–5004.